赵春林 博士，安龙生物创始人，安龙基金创始合伙人，为清华大学生物系首届毕业生，美国匹兹堡大学医学院分子生物学博士和芝加哥大学工商管理硕士，曾任美国辉瑞制药资深经理，国科嘉和及康桥资本董事总经理，拥有三十多年生命科学及医疗健康领域的创业和投资经验，投资过信达生物，贝瑞合康，天镜生物，歌礼药业，莱凯医药，康乃德及国科恒泰等杰出企业。赵春林博士曾任清华大学生命科学院，医学院及药学院首届校友会主席，为百华协会资深会员。 安龙基金是一只专注于国内早期生命科学与医疗健康领域的基金，投资领域横跨生命科学，医药研发，医疗器械，医疗服务及相关领域。 安龙生物是国内基因治疗及核酸药物领先企业，专注基因新技术及国内大市场产品的新药研发，眼科基因治疗产品已进入临床。 

Chunlin Zhao, Ph.D Founder of the AnlongBio/AnlongMed. Dr. Zhao is among the first class graduated from Biological Science and Biotechnology department at Tsinghua University in 1990. He received his Ph.D in molecular biology from University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China in 2003, he founded Beijing LongMed Inc. and later became partner of CASH and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, invested in Innovent, BerryGenomics, ASLETIS, I-Mab, Laekna, and GKHT. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association for School of Life Sciences，School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading venture fund in Chinese life sciences and Biotech, focusing on biotech & biopharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio in 2019, a leading player in genetic medicine discovery in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines, with a leading product in gene therapy for ophthalmology already in clinical stages.